PAUL ROSSER: Open Payments
NPI 1760596175 · PROVO, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,486 in 136 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $2,486
Food & beverage: $2,486
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 41 | $701 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $380 |
| Janssen Biotech, Inc. | 15 | $289 |
| Aimmune Therapeutics, Inc. | 15 | $200 |
| Madrigal Pharmaceuticals | 6 | $149 |
| Gilead Sciences, Inc. | 4 | $106 |
| Ardelyx, Inc. | 6 | $105 |
| Celltrion USA Inc. | 5 | $98 |
| GENZYME CORPORATION | 4 | $88 |
| Phathom Pharmaceuticals, Inc. | 7 | $85 |
Products named: ENTYVIO, RINVOQ, TREMFYA, LINZESS, REZDIFFRA, VOWST, DUPIXENT, IBSRELA.
Industry payments across UT — which companies pay providers there.
